Entacapone is utilized as an adjunct to levodopa therapy for the treatment of Parkinson's syndrome. According to the Biopharmaceutics Classification System, it is classified as a class IV drug. The solubility of a substance can be enhanced by utilizing nanoemulsion, which can also effectively traverse the blood-brain barrier owing to its nanoscale dimensions. The formulation utilized various proportions of Capmul Medium Chain Mono and Diglycerides as the oil phase, Pluronic F127, and Phospholipin 90 as hydrophilic and lipophilic surfactants. Optimization was performed using 32 factorial designs in Design Expert®8.0.5.2 software, incorporating mixing speed, time, and sonication parameters. The nanoemulsion exhibited an average particle size of 120.8±1.9nm, with a low polydispersity index of 0.144, indicating a uniform globule size. The zeta potential suggested good stability, while the XRD pattern indicated decreased drug crystallinity. The TEM images confirm that the size of the particles falls within the range of 120–150 nm and there is no evidence of aggregation. The drug was released at a rate of 80.33±0.92% for 8 hours. The current study demonstrates enhancements in the solubility and stability of formulated nanoemulsions designed for oral delivery.